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1. Introduction 
It is already proved that chronic administration of non-steroidal anti-inflammatory drugs 
(NSAIDs) produce multiple small intestine erosions (SI) with a higher prevalence in the 
terminal ileum (1) .This new condition is called NSAIDs induced enteropathy. In long term 
NSAIDs administration studies, almost 60 to 70% of patients were diagnosed through 
endoscopic capsules as bearing an asymptomatic enteropathy (2); characterized by increased 
intestinal permeability and mild mucosa inflammation, with hypoalbuminemia and 
deficient iron anemia(3). It was hypothesized that NSAIDs could act as liposoluble acids 
interacting with superficial membrane phospholipids, inducing a direct damage on the 
enterocyte mitochondria during the absorption. The mitochondrial damage could lead to an 
intracellular energy depletion, calcium efflux and generation of free radicals. The 
intercellular integrity is disrupted increasing the intestinal permeability, thus making the 
enterocytes more vulnerable in the lumen content, such as bacteria, bile, enzymes and 
neutrophile activation (5). 
In this hypothesis no prostaglandins are effective, where the NSAIDs COX-1/ COX-2 
inhibitors produce gastrointestinal necrosis (6) besides, we were able to prove that COX-3 
inhibition with paracetamol simultaneously with COX-1, produce multiple erosions in the 
small intestine (7), and that paracetamol aggravated the intestinal erosions produced by 
diclofenac (8). Anyway, the selective COX-1, COX-2 or COX-3 inhibition does not produce 
gastrointestinal lesions (9). 
bioflora is a well known probiotic containing 4 bacteria, i.e., lactobacillus casei, lactobacillus 
plantarum, streptococci faecalis and bifidobacterium brevis, with anti-inflammatory effect given 
either orally or sc, with live or dead bacteria (10, 11); that in stressed rats hindered the 
bacterial overgrowth, blocking neutrophiles without intestinal bacterial translocation and in 
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other organs, and increase of t lymphocytes (cd4+) (12) the aim of the present study was to 
study prevention yielded by bioflora in indo induced enteropathy, its probable mechanism 
induced by the bacterial overgrowth, the neutrophiles, the bacterial translocation and de 
cd4+ intestinal immunodeficiency. 
2. Material and methods 
Randomized female Sprague-Dawley rats groups (n=10 each one), 200g, 24h fast, water ad 
libitum, avoiding coprophagy were submitted to the following experiments: I. 30 mg/kg 
Indo, SC each12h; 2 days (control). II. 1 ml Bio (1,3x107 live bacteria), by orogastric gavage in 
bolus each 12h for 2 days and Indo. The rats were sacrificed by ether overdose, performing 
laparatomy, total gastrectomy and enterectomy, stomach aperture and small intestine to 
tabulate the macroscopic necrotic percentage by computerized planimetry. The number of 
intestinal erosions (mm2) was quantified, obtaining gastric and intestinal mucosa samples for 
histochemical examination (myeloperoxydase (MPO)). Bacteriological cultures were 
performed on mesenteric lymph nodes. Four cm terminal ileum was removed to quantified 
CD4+ T lymphocytes utilizing immunohistochemical techniques; anti-rat human antibody 
(Dakko, USA) evaluating each sample through Madsen scale. (13)  
Statistics: Student's t test and ANOVA; for the microbiological evaluation of mesenteric 
lymph nodes exact Fisher's test, and Man-Whitney's test for intestinal cultures; p<0.05 
significance was accepted. Drugs: Indomethacin (Sigma Chemical Co. St. Louis, Missouri) 
and Bioflora probiotic (Laboratorios Sidus). 
3. Results 
Percentage of macroscopic gastric lesional area is presented in table 1, demonstrating that 
the Bio-Indo Group provided a marked gastric mucosa protection (p<0.001), and MPO 
showed also a decrease of neutrophile infiltrate (p<0.02). 
In table 2, are shown the erosive intestinal area were Bioflora avoid the occurrence of Indo 
induced erosions (p<0.01) and MPO reverted also the neutrophile infiltrate. 
In table 3 can be observed the significant decrease of the intestinal bacterial overgrowth 
produced by Bio (p<0.01), as well as the bacterial translocation to the intestinal mesenteric 
lymph nodes (p<0.02) and the immunohistochemistry of the ileum mucosa. Bio restored the 
immunity showing a marked increase of T lymphocytes (CD4+). (Figure 1). 
4. Discussion 
Our results confirmed that the NSAIDs such as Indo produced marked decrease of  
small intestine immunity due T lymphocytes (CD 4+) effect, that might lead to a  
secondary bacterial overgrowth, intestinal bacterial translocation with altered intestinal 
permeability and finally occurrence of intestinal erosions. This could lead to a new 
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hypothesis since the increase of T (CD4+) that impede the bacterial overgrowth and the 
neutrophile infiltration might protect the defensive barrier avoiding the onset of NSAID 
enteropathy. 
Reuter (14), demonstrated the importance of the enteropathic circulation of NSAIDs, where 
sulindac, without effect, does not produce a damage to the small intestine; there could be 
also altered absorption of biliary salts by NSAIDs, and which is most important, loss of 
integrity of COX-1 and COX-2 (15). 
The cycloxygenase inhibition could affect the blood flow of intestinal villi, since it was 
observed microvascular injury in the jejunal villi as a previous event to the erosion 
occurrence (16). The eNOS could be administered associated with NSAIDs, since it provides 
gastrointestinal protection, but not INOS that aggravates ulceration. (17, 18) 
Misoprostol in high doses showed a mild increase of the intestinal permeability to Indo (19) 
although other works do not show such effect (20). Metronidazol that attenuate the 
intestinal inflammation and hemorrhage was also studied, although it did not modified the 
intestinal permeability (24). Sulphasalazine was also evaluated showing a slight 
improvement of the intestinal permeability (22). 
There is important to differentiate the NSAIDs induced enteropathy from others such as the 
one produced in the espondiloarthrosis, especially if NSAIDs are administered, in Crohn's 
disease (23). Patients with NSAIDs enteropathy must suppress as a first option NSAIDs, 
since the disease could persist up to a year after therapy discontinuation (24) and any kind 
of NSAIDS is forbidden, COX-2 included (25) except in patients with chronic joint pain  
and gastroduodenal ulcer risk that could be treated with naproxen, without cardiovascular 
risks and with a proton pump blocker such as esomeprazol (26).Briefly, NSAIDs 
enteropathy presents in its physiopathology a similarity with Chron's disease (27), although 
attenuated, where the theory of the inflammatory intestinal disease is actually an 
immunodeficiency with bacteria proliferation on the intestinal mucosa crypts and 
penetration of the intestinal defensive barrier. This observation Is supported by the fact that 
a-defensines production is not correlated with the disease severity(28); finally in the NSAIDs 
mucosa enteropathy a good defense of the intestinal mucosa to avoid bacterial penetration is 
to treat immunodeficiency, through probiotics prescription Live bacteria could theoretically 
prevent the damage induced by NSAIDs altering the microbial alteration induced by 
NSAIDs in the intestinal microbial ecology (30) and by immune function modulation (31). 
Anyway there were different probiotics that exacerbated the intestinal ulceration, confirmed 
with the same model of induced Indomethacin enteropathy (32). The Bioflora probiotic 
provided a marked protection of the gastrointestinal mucosa in the same indomethacin 
model. The efficacy of the drugs under study, probiotics included, depends also on the 
inhibition of the pro-inflammatory cytokines activated by the TLR4/D88 mediators, that are 
important in the intestinal pathology of Crohn's disease and NSAIDs enteropathy 
development (33, 34). 
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5. Conclusion 
We postulated that NSAID induced lesion in stomach and small intestine, by two 
mechanism different, in stomach the NSAID inhibited both COX1 and COX2 and 
provokes depletion of Prostaglandins and gastric necrosis; in contrast, the NSAID in small 
intestine produced marked decrease of the immunity due T Lymphocytes (CD4T) effect, 
that lead to a secondary bacterial permeability with the neutrophile infiltration in mucosa 
intestinal and formation of mesenteric lymph nodes; besides, the inhibition COX3 induce 
multiple erosions in small intestine. The cyclooxygenase inhibition affect the blood flow of 
intestinal villi as a previous event to the erosions occurrence. The Probiotics its increased 
T lymphocytes (CD4T), inhibited the bacterial overgrowth, the neutrophiles, the bacterial 
translocation and erosions in all the small intestine.  
 
 
 
 
 % gastric necrotic area MPO mg / protein 
INDO 65 ±7    P 410 ±31  P 
BIO-INDO 7.5 ±1.3   < 0.001 30 ±7  <0.01 
Table 1. Table 1. Gastric necrotic area percent and MPO in the INDO Group (Control) and in the Bio-Indo 
treated one. 
 
 
 
 
 Erosions in SI mm2 MPO mg / protein 
INDO 380 ±31  P 435 ± 45  P 
BIO-INDO 41 ± 6  <0.001 55 ± 11  <0.001 
Table 2. Table 2. Number of erosions on the small intestine and MPO, with marked remission in the 
BIO-INDO group. 
 
 
 
 
 SI Culture CFU 
Mesenteric lymph node 
cultures 
CD4+ Ileum 
INDO 7,5 ±3,5 x1010 P 9 (+) 1 (-) P 0,5 ±0.1 P 
BIO-INDO 2,3 ±0,8 x 105 <0.01 8 (-) 2 (-) 
< 
0.01 
4 ± 1 
< 
0.01 
Table 3. Prevention of intestinal bacterial overgrowth, bacterial translocation and increased immunity 
through T lymphocytes T (CD 4+) by Indo and Bio-lndo. 
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Figure 1. Bioflora Restored the inmunity showing a marked increase of T lymphocites (CD4t) 
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